We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
Date | Subject | Author | Discuss |
---|---|---|---|
08/2/2024 15:33 | Should has stated, dipped in at £97.70.7 | beckers2008 | |
08/2/2024 15:31 | I've been waiting patiently and finally been able to buy back in here, after a few years. SP reaction,overdone today, hopefully luckily for me? Let's wait and see. | beckers2008 | |
08/2/2024 14:55 | ‘Many investors view AstraZeneca as invincible given its success in recent years, yet its latest results showed that even the mighty can disappoint. The drugs giant missed fourth quarter earnings expectations due to more money being spent on research and development and a greater contribution from lower-margin sales in emerging markets. However, the business remains optimistic about the prospects for its cancer and rare disease drugs,’ AJ Bell analyst Russ Mould commented. | philanderer | |
08/2/2024 14:38 | Poor divi in present 5% money market funds environment. Great company but well heeled managers, along with scores of other companies paying 2-3% need to get real. The boards of these businesses don't give a f..k about shareholders-they are so well paid in any case. No recovery here until rates drop to 3% | cumnor | |
08/2/2024 14:35 | Yep the yanks pushing this further down | chc15 | |
08/2/2024 14:20 | Just topped up, I read that the fall relates to them missing Q4 projections, just, but against the 2024-5 forecast and rest of year it seems overdone | faz | |
08/2/2024 14:06 | seems a heavy fall on results that weren't that bad. took a small position to start | ric0chet | |
08/2/2024 12:28 | Looks well overdone to me. IMO it will recover | our haven | |
08/2/2024 12:07 | Me too. Suet | suetballs | |
08/2/2024 11:42 | Yeh just had a nibble at 98, then waiting for US to open and see.. | chc15 | |
08/2/2024 11:35 | Can't be far off now, surely. Might have another little plummet when stateside opens. | thamestrader | |
08/2/2024 11:14 | Ouch, what's the bottom here u think.. | chc15 | |
08/2/2024 10:43 | vaston. Grow up. | tday | |
08/2/2024 10:34 | SYME IS NOW READY TO FLY | vaston | |
08/2/2024 10:21 | Continues to disappoint. | philanderer | |
08/2/2024 09:14 | Dounbtless if profits halved market would raise price by £2.50 | holts | |
29/1/2024 15:32 | https://www.londonst | blackhorse23 | |
19/1/2024 11:52 | Ha ha https://www.alliance | blackhorse23 | |
18/1/2024 19:46 | We know you love APH but please stop pushing it everywhere! | mattboxy | |
18/1/2024 14:23 | Bought some APH today | blackhorse23 | |
17/1/2024 01:18 | "So far everything is going very well" always make me think of a guy falling off the roof of a big tower when he's half way down | smcni1968 | |
16/1/2024 11:00 | For the last six months,AZN has traded fairly predictably between £100 to £110. | steeplejack | |
16/1/2024 10:29 | UBS cuts AstraZeneca to 'sell' (buy) - price target 10,700 (13,000) pence or.. Morgan Stanley raises AstraZeneca price target to 13,400 (12,900) pence - 'overweight' | philanderer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions